title: The predictability of serum anti-Müllerian level in IVF/ICSI outcomes for patients of advanced reproductive age.
abstract: BACKGROUND
  The role of serum anti-Müllerian hormone (AMH) as predictor of in-vitro fertilization outcomes has been much debated. The aim of the present study is to investigate the practicability of combining serum AMH level with biological age as a simple screening method for counseling IVF candidates of advanced reproductive age with potential poor outcomes prior to treatment initiation.
  
  
  METHODS
  A total of 1,538 reference patients and 116 infertile patients aged greater than or equal to 40 years enrolled in IVF/ICSI cycles were recruited in this retrospective analysis. A reference chart of the age-related distribution of serum AMH level for Asian population was first created. IVF/ICSI patients aged greater than or equal to 40 years were then divided into three groups according to the low, middle and high tertiles the serum AMH tertiles derived from the reference population of matching age. The cycle outcomes were analyzed and compared among each individual group.
  
  
  RESULTS
  For reference subjects aged greater than or equal to 40 years, the serum AMH of the low, middle and high tertiles were equal or lesser than 0.48, 0.49-1.22 and equal or greater than 1.23 ng/mL respectively. IVF/ICSI patients aged greater than or equal to 40 years with AMH levels in the low tertile had the highest cycle cancellation rate (47.6%) with zero clinical pregnancy. The nadir AMH level that has achieved live birth was 0.56 ng/mL, which was equivalent to the 36.4th percentile of AMH level from the age-matched reference group. The optimum cut-off levels of AMH for the prediction of nonpregnancy and cycle cancellation were 1.05 and 0.68 ng/mL, respectively.
  
  
  CONCLUSIONS
  Two criteria: (1) age greater than or equal to 40 years and (2) serum AMH level in the lowest tertile (equal or lesser than 33.3rd percentile) of the matching age group, may be used as markers of futility for counseling IVF/ICSI candidates.
authors.affiliation: Department of Obstetrics and Gynecology, Mackay Memorial Hospital, Taipei, Taiwan.
authors.forename: Robert K K
authors.initials: RK
authors.lastname: Lee
authors.forename: Frank S Y
authors.initials: FS
authors.lastname: Wu
authors.forename: Ming-Huei
authors.initials: MH
authors.lastname: Lin
authors.forename: Shyr-Yeu
authors.initials: SY
authors.lastname: Lin
authors.forename: Yuh-Ming
authors.initials: YM
authors.lastname: Hwu
mesh_terms: D000328:Adult; D000375:Aging / Q000097:blood*; D054304:Anti-Mullerian Hormone / Q000097:blood*; D015415:Biomarkers / Q000097:blood; D005260:Female; D005307:Fertilization in Vitro; D006801:Humans; D007247:Infertility, Female / Q000097:blood* / Q000175:diagnosis* / Q000628:therapy; D008499:Medical Records; D008875:Middle Aged; D010060:Ovulation / Q000187:drug effects; D010062:Ovulation Induction; D010353:Patient Education as Topic; D011247:Pregnancy; D018873:Pregnancy Rate; D011379:Prognosis; D012372:ROC Curve; D012189:Retrospective Studies; D020554:Sperm Injections, Intracytoplasmic; D013624:Taiwan
chemical_list: D015415:Biomarkers; D054304:Anti-Mullerian Hormone